PE20231441A1 - Cocristal de un inhibidor de cdk - Google Patents
Cocristal de un inhibidor de cdkInfo
- Publication number
- PE20231441A1 PE20231441A1 PE2023001908A PE2023001908A PE20231441A1 PE 20231441 A1 PE20231441 A1 PE 20231441A1 PE 2023001908 A PE2023001908 A PE 2023001908A PE 2023001908 A PE2023001908 A PE 2023001908A PE 20231441 A1 PE20231441 A1 PE 20231441A1
- Authority
- PE
- Peru
- Prior art keywords
- cocrystal
- compound
- cdk inhibitor
- formula
- fumaric acid
- Prior art date
Links
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 title abstract 2
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 title abstract 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- CVAXNGIXLUILFO-KPGJNUASSA-N (2S)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-3-methyl-2-[3-[6-[[(E)-4-morpholin-4-ylbut-2-enoyl]amino]pyridin-3-yl]phenyl]butanamide Chemical compound CC(C)[C@H](C(NC1=NNC(C2CC2)=C1)=O)C1=CC=CC(C(C=C2)=CN=C2NC(/C=C/CN2CCOCC2)=O)=C1 CVAXNGIXLUILFO-KPGJNUASSA-N 0.000 abstract 1
- 102100026810 Cyclin-dependent kinase 7 Human genes 0.000 abstract 1
- 101000911952 Homo sapiens Cyclin-dependent kinase 7 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000001530 fumaric acid Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Analysing Materials By The Use Of Radiation (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202041055174 | 2020-12-18 | ||
| PCT/IB2021/061895 WO2022130304A1 (en) | 2020-12-18 | 2021-12-17 | Cocrystal of a cdk inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20231441A1 true PE20231441A1 (es) | 2023-09-14 |
Family
ID=80001496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023001908A PE20231441A1 (es) | 2020-12-18 | 2021-12-17 | Cocristal de un inhibidor de cdk |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20240059669A1 (https=) |
| EP (1) | EP4263534A1 (https=) |
| JP (1) | JP2023554492A (https=) |
| KR (1) | KR20230159363A (https=) |
| CN (1) | CN116685326A (https=) |
| AU (1) | AU2021402415A1 (https=) |
| CA (1) | CA3202198A1 (https=) |
| CL (1) | CL2023001753A1 (https=) |
| CO (1) | CO2023009368A2 (https=) |
| CR (1) | CR20230261A (https=) |
| DO (1) | DOP2023000126A (https=) |
| EC (1) | ECSP23054131A (https=) |
| IL (1) | IL303738A (https=) |
| MX (1) | MX2023007218A (https=) |
| PE (1) | PE20231441A1 (https=) |
| TW (1) | TW202241881A (https=) |
| WO (1) | WO2022130304A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022084930A2 (en) * | 2020-10-22 | 2022-04-28 | Aurigene Discovery Technologies Limited | Cancer therapy using a combination of cdk7 inhibitor with an anti-microtubule agent |
| US12084453B2 (en) | 2021-12-10 | 2024-09-10 | Incyte Corporation | Bicyclic amines as CDK12 inhibitors |
| WO2023224961A1 (en) | 2022-05-16 | 2023-11-23 | Exelixis, Inc. | Cancer therapy using a combination of a cdk7 inhibitor with an oral serd |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| CN118772106A (zh) * | 2024-06-07 | 2024-10-15 | 山东大学 | 伊马替尼-没食子酸共晶、其溶剂化物、制备方法和应用 |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3302448T1 (sl) | 2015-06-04 | 2024-03-29 | Aurigene Oncology Limited | Substituirani heterociklični derivati kot inhibitorji cdk |
-
2021
- 2021-12-17 PE PE2023001908A patent/PE20231441A1/es unknown
- 2021-12-17 AU AU2021402415A patent/AU2021402415A1/en not_active Abandoned
- 2021-12-17 EP EP21848027.5A patent/EP4263534A1/en active Pending
- 2021-12-17 WO PCT/IB2021/061895 patent/WO2022130304A1/en not_active Ceased
- 2021-12-17 TW TW110147455A patent/TW202241881A/zh unknown
- 2021-12-17 MX MX2023007218A patent/MX2023007218A/es unknown
- 2021-12-17 CN CN202180085401.XA patent/CN116685326A/zh active Pending
- 2021-12-17 CA CA3202198A patent/CA3202198A1/en active Pending
- 2021-12-17 US US18/257,962 patent/US20240059669A1/en active Pending
- 2021-12-17 JP JP2023537470A patent/JP2023554492A/ja active Pending
- 2021-12-17 CR CR20230261A patent/CR20230261A/es unknown
- 2021-12-17 KR KR1020237024297A patent/KR20230159363A/ko active Pending
- 2021-12-17 IL IL303738A patent/IL303738A/en unknown
-
2023
- 2023-06-15 CL CL2023001753A patent/CL2023001753A1/es unknown
- 2023-06-16 DO DO2023000126A patent/DOP2023000126A/es unknown
- 2023-07-14 CO CONC2023/0009368A patent/CO2023009368A2/es unknown
- 2023-07-18 EC ECSENADI202354131A patent/ECSP23054131A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO2023009368A2 (es) | 2023-09-29 |
| KR20230159363A (ko) | 2023-11-21 |
| ECSP23054131A (es) | 2023-09-29 |
| EP4263534A1 (en) | 2023-10-25 |
| WO2022130304A1 (en) | 2022-06-23 |
| CN116685326A (zh) | 2023-09-01 |
| MX2023007218A (es) | 2023-07-27 |
| CA3202198A1 (en) | 2022-06-23 |
| JP2023554492A (ja) | 2023-12-27 |
| US20240059669A1 (en) | 2024-02-22 |
| CR20230261A (es) | 2023-10-04 |
| IL303738A (en) | 2023-08-01 |
| TW202241881A (zh) | 2022-11-01 |
| DOP2023000126A (es) | 2023-11-30 |
| AU2021402415A1 (en) | 2023-07-06 |
| CL2023001753A1 (es) | 2024-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20231441A1 (es) | Cocristal de un inhibidor de cdk | |
| PE20231438A1 (es) | Proceso para hacer un inhibidor de pd-1/pd-l1 y sales y formas cristalinas del mismo | |
| JOP20210001A1 (ar) | مشتقات 3-(5- هيدروكسي -1- أوكسو أيزو إندولين -2- يل) بيبريدين -2، 6- دايون واستخدامها لمعالجة أمراض مرتبطة ببروتين ذات أصبع الزنك من عائلة (ikaros 2 (ikzf2 | |
| JOP20210319A1 (ar) | مركبات بيروليدين | |
| JOP20220069A1 (ar) | عوامل محللة لـ brd9 ثنائية الوظيفة وطرق لاستخدامها | |
| MX2021001752A (es) | Compuestos de pirrolo-dipiridina. | |
| TNSN06064A1 (en) | 5-phenyl-4-methyl-thiazol-2-yl-amine derivatives as inhibitors of phosphatidylinositol 3 kinase enzymes (pi3) for the treatment of inflammatory airway diseases | |
| ES2018113A6 (es) | Procedimiento de preparacion de derivados de 4h-1-benzopiran-4-ona o sus sales. | |
| MY207696A (en) | 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof | |
| BR0309343A (pt) | Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas | |
| PE20030347A1 (es) | Composiciones farmaceuticas, kits y procedimientos que comprenden combinaciones de agonistas/antagonistas de estrogenos, estrogenos y progestinas | |
| GEAP202516802A (en) | Protac chimeric compound, preparation method thereof and use thereof | |
| UY39866A (es) | Sales y formas en estado sólido de un compuesto inhibidor de kif18a | |
| BR0316458A (pt) | Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto | |
| AR119614A1 (es) | Formas en estado sólido de (s)-2-(((s)-6,8-diflúor-1,2,3,4-tetrahidronaftalen-2-il)amino)-n-(1-(2-metil-1-(neopentilamino)propan-2-il)-1h-imidazol-4-il)pentanamida y usos de la misma | |
| AR120799A1 (es) | 2-[4-cloro-6-[2-[4-[[4-(hidroximetil)-1-piperidil]metil]fenil]etinil]-1-oxoisoindolin-2-il]-2-(6,7-dihidro-5h-pirrolo[1,2-c]imidazol-1-il)-n-tiazol-2-il-acetamida como inhibidor de egfr | |
| AR022857A1 (es) | Acido dihidroxilado de ciclo abierto y sales de los inhibidores de hmg-co-a reductasa | |
| TN2009000452A1 (en) | [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl] -5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof | |
| RU2006128788A (ru) | Производные фенил[4-(3-фенил-1н-пиразол-4-ил)пиримидин-2-ил] амина в качестве igf-1r ингибиторов | |
| BRPI0512252A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, formulação farmacêutica, uso de um composto, método de tratamento de uma doença, produto combinado, e, processo para a preparação de um composto | |
| DE60225943D1 (de) | Topoisomerase-giftmittel | |
| MX2010010561A (es) | Derivados tiazol de benzofenona utiles para inhibir la formacion del microtúbulo, y método para producir los mismos. | |
| RU2007136782A (ru) | Ингибирующие вич 2-(4-цианофенил)-6-гидроксиламинопиримидины | |
| MX2021009188A (es) | Uso de composición que contiene inhibidor de quinasa dependiente de ciclina 4/6 en combinación con anastrozol en la preparación de medicamentos para el tratamiento de enfermedades tumorales. | |
| CN109311817A (zh) | 取代的含氮芳环化合物及其应用 |